Kalvista Pharmaceuticals Company Insiders
KALV Stock | USD 10.15 0.83 8.91% |
Slightly above 53% of Kalvista Pharmaceuticals' sophisticated investors are presently acquiring. The analysis of the overall insider sentiment regarding Kalvista Pharmaceuticals suggests that some insiders are bullish. Kalvista Pharmaceuticals employs about 150 people. The company is managed by 14 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 10.71 employees per reported executive.
Benjamin Palleiko President Chief President |
Kalvista Pharmaceuticals' Insider Buying Vs Selling
53
Selling | Buying |
Latest Trades
2024-11-18 | Benjamin L Palleiko | Disposed 14400 @ 9.26 | View | ||
2024-09-09 | Benjamin L Palleiko | Disposed 7352 @ 12.19 | View | ||
2024-08-23 | Paul K Audhya | Disposed 2135 @ 12.4 | View | ||
2024-08-19 | Christopher Yea | Disposed 7102 @ 12.01 | View | ||
2024-06-07 | Benjamin L Palleiko | Disposed 7465 @ 11.53 | View | ||
2024-05-20 | Edward P Feener | Disposed 8088 @ 11.76 | View | ||
2024-02-20 | Edward P Feener | Disposed 28288 @ 14.07 | View | ||
2024-02-08 | Venrock Healthcare Capital Par | Acquired 29747 @ 14.7 | View | ||
2024-02-06 | Venrock Healthcare Capital Par | Acquired 4474 @ 14.74 | View | ||
2024-01-29 | Venrock Healthcare Capital Par | Acquired 80600 @ 14.22 | View | ||
2024-01-26 | Venrock Healthcare Capital Par | Acquired 4174 @ 12.98 | View | ||
2024-01-24 | Venrock Healthcare Capital Par | Acquired 20686 @ 12.44 | View | ||
2024-01-22 | Venrock Healthcare Capital Par | Acquired 67546 @ 12.55 | View | ||
2024-01-18 | Venrock Healthcare Capital Par | Acquired 39680 @ 12.51 | View | ||
2024-01-16 | Venrock Healthcare Capital Par | Acquired 19599 @ 12.73 | View |
Monitoring Kalvista Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Kalvista |
Kalvista Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kalvista Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Kalvista will maintain a workforce of slightly above 150 employees by December 2024.Kalvista Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.16 in 2024, whereas Return On Tangible Assets are likely to drop (1.09) in 2024. At this time, Kalvista Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1 M in 2024, whereas Other Current Assets are likely to drop slightly above 1 M in 2024.Common Stock Shares Outstanding is likely to climb to about 38.6 M in 2024, whereas Net Loss is likely to drop (26.1 M) in 2024.
Kalvista Pharmaceuticals Workforce Comparison
Kalvista Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,859. Kalvista Pharmaceuticals holds roughly 150 in number of employees claiming about 4% of equities under Health Care industry.
Kalvista Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kalvista Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kalvista Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kalvista Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.6667 | 8 | 12 | 110,225 | 89,894 |
2024-09-01 | 0.3889 | 7 | 18 | 183,968 | 124,661 |
2024-06-01 | 0.3636 | 8 | 22 | 281,848 | 197,145 |
2024-03-01 | 1.0 | 36 | 36 | 2,414,704 | 493,227 |
2023-12-01 | 0.3636 | 8 | 22 | 624,321 | 191,175 |
2023-09-01 | 0.5217 | 12 | 23 | 173,294 | 189,375 |
2023-06-01 | 0.4 | 6 | 15 | 76,971 | 53,805 |
2023-03-01 | 0.5789 | 11 | 19 | 317,244 | 72,818 |
2022-12-01 | 0.9 | 9 | 10 | 54,191 | 19,089 |
2022-09-01 | 0.25 | 3 | 12 | 9,996 | 26,931 |
2022-03-01 | 0.6667 | 2 | 3 | 57,657 | 67,657 |
2021-09-01 | 1.25 | 5 | 4 | 50,000 | 21,000 |
2021-06-01 | 0.4444 | 16 | 36 | 676,558 | 400,896 |
2021-03-01 | 0.7895 | 15 | 19 | 391,142 | 125,284 |
2020-12-01 | 0.8095 | 17 | 21 | 587,044 | 90,316 |
2019-12-01 | 0.5833 | 7 | 12 | 28,355 | 24,710 |
2019-09-01 | 2.2 | 11 | 5 | 135,002 | 28,010 |
2019-06-01 | 0.4074 | 11 | 27 | 201,828 | 221,938 |
2019-03-01 | 0.0851 | 4 | 47 | 21,355 | 1,373,239 |
2018-12-01 | 0.4 | 4 | 10 | 28,000 | 60,440 |
2018-09-01 | 9.0 | 9 | 1 | 1,491,148 | 2,500 |
2017-12-01 | 0.3333 | 3 | 9 | 2,265,065 | 2,725,283 |
2017-09-01 | 1.0 | 7 | 7 | 42,000 | 353,291 |
2016-12-01 | 1.8 | 18 | 10 | 7,482,195 | 79,801 |
2015-12-01 | 0.5 | 1 | 2 | 10,000 | 20,000 |
2015-06-01 | 1.6552 | 48 | 29 | 30,130,798 | 10,321,258 |
Kalvista Pharmaceuticals Notable Stakeholders
A Kalvista Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kalvista Pharmaceuticals often face trade-offs trying to please all of them. Kalvista Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kalvista Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Benjamin Palleiko | Chief President | Profile | |
Stephen Donnelly | Director Secretary | Profile | |
Jarrod Aldom | Vice Communications | Profile | |
Nicole Sweeny | Chief Officer | Profile | |
Ryan Baker | Head Relations | Profile | |
Brian Piekos | Chief Officer | Profile | |
John McKune | VP Fin | Profile | |
Thomas MBA | CEO Director | Profile | |
Michael PharmD | Senior Development | Profile | |
Christopher Yea | Chief Development Officer | Profile | |
MD MBA | Chief Officer | Profile | |
Rachel Morten | Senior QA | Profile | |
Edward Feener | Chief Scientific Officer | Profile | |
Brian JD | General Counsel | Profile |
About Kalvista Pharmaceuticals Management Performance
The success or failure of an entity such as Kalvista Pharmaceuticals often depends on how effective the management is. Kalvista Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kalvista management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kalvista management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.54) | (1.09) | |
Return On Capital Employed | (0.66) | 18.02 | |
Return On Assets | (0.54) | (1.09) | |
Return On Equity | (0.61) | 0.16 |
Please note, the imprecision that can be found in Kalvista Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kalvista Pharmaceuticals. Check Kalvista Pharmaceuticals' Beneish M Score to see the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
Kalvista Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Kalvista Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kalvista Pharmaceuticals within its industry.Kalvista Pharmaceuticals Manpower Efficiency
Return on Kalvista Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 844.3K | |
Net Loss Per Executive | 9M | |
Working Capital Per Employee | 1.4M | |
Working Capital Per Executive | 14.5M |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.